Lia DeGroot

A House pan­el is prob­ing the FDA over how it has al­lowed a com­mon in­gre­di­ent in over-the-counter cold med­ica­tions to stay on the mar­ket for

The FTC on Mon­day filed an am­i­cus brief in My­lan Phar­ma­ceu­ti­cals’ an­titrust law­suit al­leg­ing that Sanofi abused the FDA’s Or­ange Book to de­lay and block

Sen­ate Health Com­mit­tee Chair Bernie Sanders (I-VT) and fel­low De­moc­rats on Tues­day an­nounced that the CEOs of John­son & John­son, Mer­ck and Bris­tol My­ers Squibb

As RSV cas­es start to rise this sea­son, As­traZeneca and Sanofi have strug­gled to match the de­mand for their new mon­o­clon­al an­ti­body to pro­tect against

Pfiz­er and Astel­las on Thurs­day nabbed an ex­pand­ed ap­proval for Xtan­di (en­za­lu­tamide) to treat non-metasta­t­ic cas­tra­tion-sen­si­tive prostate can­cer with bio­chem­i­cal re­cur­rence at high risk for

Pres­i­dent Joe Biden se­lect­ed Van­der­bilt Uni­ver­si­ty’s med­i­cine chair Kim­ryn Rath­mell to serve as the next di­rec­tor of the Na­tion­al Can­cer In­sti­tute, the White House an­nounced

The FDA on Thurs­day ap­proved Mer­ck’s an­ti-PD-1 ther­a­py to treat a type of gas­troin­testi­nal can­cer in com­bi­na­tion with chemother­a­py, mark­ing the drug’s 38th in­di­ca­tion. The

More than 50 House De­moc­rats are call­ing on the FDA, HHS and the Of­fice for Civ­il Rights to pro­tect ac­cess to miso­pros­tol and methotrex­ate, which

As the FDA seeks to bring a greater fo­cus to im­prov­ing post-mar­ket ev­i­dence gen­er­a­tion, a new re­port from the Rea­gan-Udall Foun­da­tion of­fers some po­ten­tial so­lu­tions

The new leader of the NIH is wor­ried about obe­si­ty. Mon­i­ca Bertag­nol­li, who was con­firmed as the new NIH di­rec­tor last week, said that dur­ing